Stephanie L. Battle

Stephanie L. Battle

Auto-generated profile, based on publicly available information

Stephanie L. Battle

McKusick–Nathans Institute, Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2024 in Nature
Verified
Journal Article
Closed access
PDF file
NLNicole J. Lake
Nicole J. Lake
KMKaiyue Ma
Kaiyue Ma
WLWei Liu
Wei Liu
SBStephanie L. Battle
Stephanie L. Battle
KLKristen M. Laricchia
Kristen M. Laricchia
MLMonkol Lek
Monkol Lek

30 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YHYun Soo Hong
Yun Soo Hong
SBStephanie L. Battle
Stephanie L. Battle
WSWen Shi
Wen Shi
DPDaniela Puiu
Daniela Puiu
VPVamsee Pillalamarri
Vamsee Pillalamarri
DADan E. Arking
Dan E. Arking
Mitochondria carry their own circular genome and disruption of the mitochondrial genome is associated with various aging-related diseases. Unlike the nuclear genome, mitochondrial DNA (mtDNA) can be present at 1000 s to 10,000 s copies in somatic cells and variants may exist in a state of heteroplasmy, where only a fraction of the DNA molecules harbors a particular variant. We quantify mtDNA heteroplasmy in 194,871 participants in the UK Biobank and find that heteroplasmy is associated with a 1.5-fold increased risk of all-cause mortality. Additionally, we functionally characterize mtDNA single nucleotide variants (SNVs) using a constraint-based score, mitochondrial local constraint score sum (MSS) and find it associated with all-cause mortality, and with the prevalence and incidence of cancer and cancer-related mortality, particularly leukemia. These results indicate that mitochondria may have a functional role in certain cancers, and mitochondrial heteroplasmic SNVs may serve as a prognostic marker for cancer, especially for leukemia.

17 May 2022 in NAR Genomics and Bioinformatics
Verified
Journal Article
Open access
PDF file
SBStephanie L Battle
Stephanie L Battle
DPDaniela Puiu
Daniela Puiu
TGTOPMed mtDNA Working Group
TOPMed mtDNA Working Group
JVJoost Verlouw
Joost Verlouw
LBLinda Broer
Linda Broer
DADan E Arking
Dan E Arking
Mitochondrial diseases are a heterogeneous group of disorders that can be caused by mutations in the nuclear or mitochondrial genome. Mitochondrial DNA (mtDNA) variants may exist in a state of heteroplasmy, where a percentage of DNA molecules harbor a variant, or homoplasmy, where all DNA molecules have the same variant. The relative quantity of mtDNA in a cell, or copy number (mtDNA-CN), is associated with mitochondrial function, human disease, and mortality. To facilitate accurate identification of heteroplasmy and quantify mtDNA-CN, we built a bioinformatics pipeline that takes whole genome sequencing data and outputs mitochondrial variants, and mtDNA-CN. We incorporate variant annotations to facilitate determination of variant significance. Our pipeline yields uniform coverage by remapping to a circularized chrM and by recovering reads falsely mapped to nuclear-encoded mitochondrial sequences. Notably, we construct a consensus chrM sequence for each sample and recall heteroplasmy against the sample's unique mitochondrial genome. We observe an approximately 3-fold increased association with age for heteroplasmic variants in non-homopolymer regions and, are better able to capture genetic variation in the D-loop of chrM compared to existing software. Our bioinformatics pipeline more accurately captures features of mitochondrial genetics than existing pipelines that are important in understanding how mitochondrial dysfunction contributes to disease.

1 September 2017 in Stem Cell Reports
Verified
Journal Article
Open access
KPKalyan K. Pasumarthy
Kalyan K. Pasumarthy
NJNaresh Doni Jayavelu
Naresh Doni Jayavelu
LKLotta Kilpinen
Lotta Kilpinen
CAColin Andrus
Colin Andrus
SBStephanie L. Battle
Stephanie L. Battle
R. David HawkinsR. David Hawkins
R. David Hawkins
Human bone marrow stromal cells, or mesenchymal stem cells (BM-MSCs), need expansion prior to use as cell-based therapies in immunological and tissue repair applications. Aging and expansion of BM-MSCs induce epigenetic changes that can impact therapeutic outcomes. By applying sequencing-based methods, we reveal that the breadth of DNA methylation dynamics associated with aging and expansion is greater than previously reported. Methylation changes are enriched at known distal transcription factor binding sites such as enhancer elements, instead of CpG-rich regions, and are associated with changes in gene expression. From this, we constructed hypo- and hypermethylation-specific regulatory networks, including a sub-network of BM-MSC master regulators and their predicted target genes, and identified putatively disrupted signaling pathways. Our genome-wide analyses provide a broader overview of age- and expansion-induced DNA methylation changes and a better understanding of the extent to which these changes alter gene expression and functionality of human BM-MSCs.

30 December 2021 in medRxiv
Verified
Preprint
Open access
PDF file
SBStephanie L Battle
Stephanie L Battle
DPDaniela Puiu
Daniela Puiu
TGTOPMed mtDNA Working Group
TOPMed mtDNA Working Group
EBEric Boerwinkle
Eric Boerwinkle
KTKent D Taylor
Kent D Taylor
DADan Arking
Dan Arking
Mitochondrial diseases are a heterogeneous group of disorders that can be caused by mutations in the nuclear or mitochondrial genome. Mitochondrial DNA variants may exist in a state of heteroplasmy, where a percentage of DNA molecules harbor a variant, or homoplasmy, where all DNA molecules have a variant. The relative quantity of mtDNA in a cell, or copy number (mtDNA-CN), is associated with mitochondrial function, human disease, and mortality. To facilitate accurate identification of heteroplasmy and quantify mtDNA-CN, we built a bioinformatics pipeline that takes whole genome sequencing data and outputs mitochondrial variants, and mtDNA-CN. We incorporate variant annotations to facilitate determination of variant significance. Our pipeline yields uniform coverage by remapping to a circularized chrM and recovering reads falsely mapped to nuclear-encoded mitochondrial sequences. Notably, we construct a consensus chrM sequence for each sample and recall heteroplasmy against the sample’s unique mitochondrial genome. We observe an approximately 3-fold increased association with age for heteroplasmic variants in non-homopolymer regions and, are better able to capture genetic variation in the D-loop of chrM compared to existing software. Our bioinformatics pipeline more accurately captures features of mitochondrial genetics than existing pipelines that are important in understanding how mitochondrial dysfunction contributes to disease.